NAP (davunetide) provides functional and structural neuroprotection

Illana Gozes*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


NAP (davunetide) is an eight amino acid peptide (NAPVSIPQ) that has been shown to provide potent neuroprotection, in vitro and in vivo. In human clinical trials, NAP has been shown to increase memory scores in patients suffering from amnestic mild cognitive impairment, a precursor to Alzheimer's disease and to enhance functional daily behaviors in schizophrenia patients. NAP is derived from activity-dependent neuroprotective protein (ADNP) a molecule that is essential for brain formation, interacting with the chromatin associated protein alpha and the chromatin remodeling complex SWI/SNF and regulating >400 genes during embryonic development. Partial loss in ADNP results in cognitive deficits and pathology of the microtubule associated protein tau (tauopathy) that is ameliorated in part by NAP replacement therapy. Recent studies increased the scope of NAP neuroprotection and provided further insights into the NAP mechanisms of action. Thus, it has been hypothesized that the presence of tau on axonal microtubules renders them notably less sensitive to the microtubule-severing protein katanin, and NAP was shown to protect microtubules from katanin disruption in the face of reduced tau expression. Parallel studies showed that NAP reduced the number of apoptotic neurons through activation of PI-3K/Akt pathway in the cortical plate or both PI-3K/Akt and MAPK/MEK1 kinases in the white matter. The interaction of these disparate yet complementary pathways is the subject of future studies towards human brain neuroprotection in the clinical scenario.

Original languageEnglish
Pages (from-to)1040-1044
Number of pages5
JournalCurrent Pharmaceutical Design
Issue number10
StatePublished - Apr 2011


  • Activity-dependent neuroprotective protein (ADNP)
  • Alzheimer's disease
  • Behavior
  • Cognition
  • Davunetide
  • Developmental disorders
  • Drug discovery and development
  • Frontotemporal dementia
  • Immune interactions
  • Microtubules
  • NAP
  • Neurodegeneration
  • Neuroprotection
  • Parkinson disease
  • Progressive supranuclear palsy (PSP)
  • Retina
  • Schizophrenia
  • Tau
  • Tauopathy
  • Tubulin


Dive into the research topics of 'NAP (davunetide) provides functional and structural neuroprotection'. Together they form a unique fingerprint.

Cite this